Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pyrazofurin was administered to 21 patients with solid tumors at a dose of 200 mg/m2 iv weekly, because this dose had been shown to be well-tolerated and pharmacologic effects of a single dose at this level persisted for up to 7 days. An anemia consistent with a disturbance in rbc production was seen in most patients. Other toxic effects included stomatitis, rash, and myelosuppression. No complete or partial responses were noted, but two patients with alveolar cell carcinoma of the lung each had stable disease for 12 months. Most of the patients in this study tolerated the weekly dosage schedule well with only minimal myelosuppression, suggesting that this agent and schedule might be acceptable for use in combination chemotherapy. Several theoretic reasons favor the use of pyrazofurin in this manner. Pyrazofurin should also be evaluated more fully in patients with polycythemia vera, mycosis fungoides, and psoriasis, since other orotidylate decarboxylase inhibitors have been shown to be effective in these diseases.
 ...
PMID:Clinical trial of weekly pyrazofurin. 15 7

This case report discusses a 42-year-old male patient who presented with migratory stomatitis located on the labial and buccal mucosa and the lateral tongue border. The lesions were circumscribed, flat, smooth, and red in color with a slightly raised white border varying in size from 3 mm to over 1 cm. Duration was between 7 and 14 days and healing transpired without scarring. Follow-up continued for approximately 1 year and at each visit several lesions were seen. The possibility of stress and heredity as positive factors was considered, but with so few reported cases conclusions would be purely speculative. The absence of dermatologic pathology does not aid in establishing a relationship with psoriasis, however there is a microscopic similarity. An almost total lack of clinical symptoms may contribute to this sparse documentation, therefore dental practitioners should be articularly observant when examining oral soft tissues. Further recognition and investigation is necessary before a cause can be discovered.
 ...
PMID:Migratory stomatitis: a case report. 26 77

Stomatitis areata migrans was found in 5.4 percent of patients with psoriasis compared to 1 percent of control patients, while benign migratory glossitis was identified in 10.3 percent of patients with psoriasis and 2.5 percent of control patients. The association of these disorders with psoriasis indicates that they may be manifestations of psoriasis of the oral mucosa.
 ...
PMID:Oral lesions in patients with psoriasis: a controlled study. 152 93

The macro- and microscopic appearance and results of microbiologic and immunohistochemical investigations in six patients with geographic stomatitis are described. On the background of similarities in both the clinical, histologic and immunohistochemical findings it is felt that psoriasis and stomatitis geographica are related lesions.
 ...
PMID:Geographic stomatitis: report of 6 cases. 180 87

A clinical phase I-II evaluation of 2-amino-1,3,4-thiadiazole (A-TDA) administered daily, twice a week, or weekly was undertaken, in which 71 patients were treated with a range of doses from 2 mg/m2 to 200 mg/m2. Pharmacokinetic studies employing high-performance liquid chromatography (HPLC) demonstrated a terminal (beta) serum half-life of 2.19 h. Stomatitis, dermatitis, nausea, vomiting, and lethargy were observed. No significant leukopenia or thrombocytopenia, however, was noted. A-TDA administration led to hyperuricemia, which was adequately controlled with concurrent administration of allopurinol. Antitumor responses included one partial response in a patient with large cell carcinoma of the lung and three objective responses (2 non-small cell lung and 1 squamous cell carcinoma of the esophagus). Two patients with adenocarcinoma of the lung had a marked improvement of psoriasis during A-TDA therapy. Further phase II studies in patients with cancer and trials in patients with psoriasis are recommended.
 ...
PMID:Clinical and clinical pharmacologic studies of 2-amino-1,3,4-thiadiazole (A-TDA:NSC 4728). 293 41

5 new cases of geographic stomatitis are presented and added to a review of 32 similar cases reported in the literature up to 1987. Furthermore, a series of 70 consecutive patients with psoriasis were examined for oral mucosal lesions. Based upon the findings of the literature and the results of the present study, there seems insufficient proof to consider geographic stomatitis an oral manifestation of psoriasis.
 ...
PMID:Geographic stomatitis and psoriasis. 313 17

Methotrexate is the drug with the highest long-term continuation rate in rheumatoid arthritis patients. However, toxicity is the main reason for methotrexate withdrawal. Most adverse effects are mild abnormalities, such as digestive symptoms, stomatitis, elevations in transaminase levels, and moderate decreases in peripheral blood cell counts. Potentially life-threatening effects include hypersensitivity pneumonitis and pancytopenia. Cirrhosis is less common than in patients with psoriasis. Opportunistic infections and Epstein-Barr virus-related lymphomas have been reported. Neurological disorders, cutaneous reactions and renal lesions have been ascribed to low-dose methotrexate. Prior renal dysfunction and concomitant administration of a number of drugs, including cotrimoxazole, have been shown to increase methotrexate toxicity. However, susceptibility to the toxic effects of methotrexate varies widely across individuals. The effectiveness of folate supplementation in preventing methotrexate toxicity remains controversial.
 ...
PMID:[Side-effects during treatment of rheumatoid arthritis with methotrexate]. 781 88

Methotrexate's mechanism of action affects both the inflammatory and immunosuppressive aspects of response. Its kinetics are defined and include variable absorption, intracellular metabolism, and both renal and biliary excretion. Methotrexate is clearly effective in the treatment of rheumatoid arthritis and may be able to decrease the rate of formation of new bony erosions. It is also effective in psoriatic arthritis and is being used in a multiplicity of other rheumatic diseases. The most common toxicities ascribed to methotrexate are gastrointestinal (e.g. stomatitis) and central nervous system (e.g. headache, fatigue, malaise). Methotrexate-induced hepatic cirrhosis is less common in rheumatoid arthritis than previously thought, although its occurrence in psoriasis is probably higher than in rheumatoid arthritis. Haematological, renal and pulmonary toxicity occur, but are rare, while teratogenicity is well documented. A new and disturbing adverse event, pseudolymphomas are being reported at present.
 ...
PMID:The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. 971 72

A 71-year-old man with psoriasis developed acute methotrexate toxicity after taking 10 mg daily on his own. A few days after, he showed painful erosions of psoriatic plaques and stomatitis. In addition to those mucocutaneous lesions, the clinical background includes bone marrow and intestinal involvement. The present clinical case underlies the relevance in selecting psoriasis patients regarding methotrexate treatment, following the particular guidelines.
 ...
PMID:[Acute methotrexate toxicity in psoriasis]. 1059 92

Methotrexate has a long history of use in the treatment of various immunologic diseases, including rheumatoid arthritis and psoriasis. Although the drug is usually prescribed by a subspecialist, a family physician may assume responsibility for monitoring methotrexate therapy. Major toxic effects, such as hepatic, pulmonary, renal and bone marrow abnormalities, require careful monitoring. Minor toxic effects, such as stomatitis, malaise, nausea, diarrhea, headaches and mild alopecia, are common but respond to folate supplementation. Methotrexate is administered once weekly as a single dose or in divided doses given over a 24-hour period. To reduce the incidence of major toxic effects, methotrexate should never be given in daily doses. Relative contraindications include renal dysfunction, liver disease, active infectious disease and excessive alcohol consumption. Both women and men of reproductive age should use birth control during methotrexate therapy. Potential drug interactions include salicylates and nonsteroidal anti-inflammatory drugs, which are both commonly used in patients with rheumatoid arthritis or psoriasis. A premethotrexate evaluation is important to ensure proper patient selection for this effective but potentially toxic drug.
 ...
PMID:A family physician's guide to monitoring methotrexate. 1103 77


1 2 Next >>